COMMUNIQUÉS West-GlobeNewswire

-
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
02/04/2024 -
Indegene Hosts Inaugural Strategic Advisory Board Meeting Chaired By Renowned Global Biopharma Leader Jill DeSimone
02/04/2024 -
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
02/04/2024 -
Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference
02/04/2024 -
Novo Nordisk A/S - share repurchase programme
02/04/2024 -
Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types
02/04/2024 -
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
02/04/2024 -
RadNet Announces Outpatient Radiology Partnership with Providence Health System to Include Seven Centers in Burbank, Santa Clarita and the Northern San Fernando Valley of Los Angeles
02/04/2024 -
BioPorto A/S to Host Annual Earnings Webcast
02/04/2024 -
Crossject advances in its U.S. Strategy and reports Financial Results for 2023
02/04/2024 -
Crossject poursuit sa stratégie de développement aux États-Unis et publie ses résultats financiers pour 2023
02/04/2024 -
Transactions in Connection with Share Buy-back Program
02/04/2024 -
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
02/04/2024 -
BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer
02/04/2024 -
ONWARD® Medical Submits De Novo Application to FDA for its ARC-EX® System
02/04/2024 -
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology
02/04/2024 -
OSE Immunotherapeutics annonce une publication sur CLEC-1, point de contrôle immunitaire innovant, dans la revue à Comité de lecture Journal of Immunology
02/04/2024 -
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
02/04/2024 -
Ipsen et Sutro Biopharma annoncent la signature d'un accord exclusif de licence mondiale pour un conjugué anticorps-petite molecule ciblant les tumeurs solides
02/04/2024
Pages